A Contrarian View Of MedImmune V. Genentech

Law360, New York (February 7, 2007, 12:00 AM EST) -- The Supreme Court's eagerly anticipated January 9 decision in MedImmune v. Genentech has led to the usual crush of commentary. Many lawyers rushed to proclaim it a significant reversal of established patent law resulting in the death of the principle of “licensee estoppel.”

They foretold radical changes in the relationships between licensors and licensees that would upset settled expectations and lead to greatly increased litigation, the code word for chaos. In the words of the apt Gershwin tune, “It ain’t necessarily so.”

The sky is not...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.